LeMaitre Vascular (NASDAQ: LMAT) recently received a number of ratings updates from brokerages and research firms:

  • 8/1/2017 – LeMaitre Vascular was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $38.00 price target on the stock. According to Zacks, “LEMAITRE VASCULAR, INC. is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “
  • 7/30/2017 – LeMaitre Vascular had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $32.00 price target on the stock, up previously from $29.00.
  • 7/28/2017 – LeMaitre Vascular was upgraded by analysts at Benchmark Co. from a “hold” rating to a “buy” rating.
  • 7/25/2017 – LeMaitre Vascular was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/10/2017 – LeMaitre Vascular was downgraded by analysts at Benchmark Co. from a “buy” rating to a “hold” rating. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 7/10/2017 – LeMaitre Vascular was downgraded by analysts at Canaccord Genuity from a “buy” rating to a “hold” rating. They now have a $28.00 price target on the stock.
  • 7/4/2017 – LeMaitre Vascular was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “LEMAITRE VASCULAR, INC. is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) traded up 0.32% on Tuesday, hitting $34.06. 200,834 shares of the company traded hands. The firm’s 50 day moving average price is $30.31 and its 200-day moving average price is $27.02. The stock has a market capitalization of $640.84 million, a price-to-earnings ratio of 48.66 and a beta of 0.65. LeMaitre Vascular, Inc. has a 1-year low of $16.80 and a 1-year high of $36.09.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.06. The company had revenue of $25.80 million during the quarter, compared to the consensus estimate of $25.42 million. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. LeMaitre Vascular’s revenue was up 15.2% on a year-over-year basis. During the same period last year, the company earned $0.14 earnings per share. On average, equities research analysts expect that LeMaitre Vascular, Inc. will post $0.80 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Wednesday, August 23rd will be given a $0.055 dividend. The ex-dividend date of this dividend is Monday, August 21st. This represents a $0.22 dividend on an annualized basis and a yield of 0.65%. LeMaitre Vascular’s dividend payout ratio is presently 31.88%.

In related news, insider David B. Roberts sold 48,317 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $33.12, for a total value of $1,600,259.04. Following the completion of the sale, the insider now directly owns 30,105 shares in the company, valued at $997,077.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David B. Roberts sold 39,531 shares of the firm’s stock in a transaction on Thursday, May 11th. The stock was sold at an average price of $30.37, for a total value of $1,200,556.47. Following the completion of the sale, the insider now owns 7,414 shares of the company’s stock, valued at $225,163.18. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 278,088 shares of company stock valued at $8,936,990. 23.70% of the stock is owned by corporate insiders.

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Receive News & Ratings for LeMaitre Vascular Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc and related companies with MarketBeat.com's FREE daily email newsletter.